These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25801557)

  • 1. Population pharmacokinetic analysis of voriconazole from a pharmacokinetic study with immunocompromised Japanese pediatric subjects.
    Muto C; Shoji S; Tomono Y; Liu P
    Antimicrob Agents Chemother; 2015; 59(6):3216-23. PubMed ID: 25801557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing.
    Dolton MJ; Mikus G; Weiss J; Ray JE; McLachlan AJ
    J Antimicrob Chemother; 2014 Jun; 69(6):1633-41. PubMed ID: 24554646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients.
    Mori M; Kobayashi R; Kato K; Maeda N; Fukushima K; Goto H; Inoue M; Muto C; Okayama A; Watanabe K; Liu P
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1004-13. PubMed ID: 25451051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles.
    Chung H; Lee H; Han HK; An H; Lim KS; Lee YJ; Cho JY; Yoon SH; Jang IJ; Yu KS
    Drug Des Devel Ther; 2015; 9():2609-16. PubMed ID: 25999694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.
    Kadam RS; Van Den Anker JN
    Clin Pharmacokinet; 2016 Sep; 55(9):1031-43. PubMed ID: 26979736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients.
    Lin XB; Li ZW; Yan M; Zhang BK; Liang W; Wang F; Xu P; Xiang DX; Xie XB; Yu SJ; Lan GB; Peng FH
    Br J Clin Pharmacol; 2018 Jul; 84(7):1587-1597. PubMed ID: 29607533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.
    Driscoll TA; Yu LC; Frangoul H; Krance RA; Nemecek E; Blumer J; Arrieta A; Graham ML; Bradfield SM; Baruch A; Liu P
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5770-9. PubMed ID: 21968355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers.
    Lee S; Kim BH; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    J Clin Pharmacol; 2012 Feb; 52(2):195-203. PubMed ID: 21383338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.
    Driscoll TA; Frangoul H; Nemecek ER; Murphey DK; Yu LC; Blumer J; Krance RA; Baruch A; Liu P
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5780-9. PubMed ID: 21911570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of flavin-containing monooxygenase 3 and CYP2C19 genotypes on plasma disposition and adverse effects of voriconazole administered orally in immunocompromised patients.
    Yamada T; Mino Y; Naito T; Kawakami J
    J Infect Chemother; 2019 Dec; 25(12):1019-1025. PubMed ID: 31239195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invasive Aspergillus infection requiring lobectomy in a CYP2C19 rapid metabolizer with subtherapeutic voriconazole concentrations.
    Hicks JK; Gonzalez BE; Zembillas AS; Kusick K; Murthy S; Raja S; Gordon SM; Hanna R
    Pharmacogenomics; 2016 May; 17(7):663-7. PubMed ID: 27143031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics of Voriconazole in Chinese Patients with Hematopoietic Stem Cell Transplantation.
    Chen C; Yang T; Li X; Ma L; Liu Y; Zhou Y; Ren H; Cui Y
    Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):659-668. PubMed ID: 31041728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis.
    Liu P; Mould DR
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4718-26. PubMed ID: 24913161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients.
    Li ZW; Peng FH; Yan M; Liang W; Liu XL; Wu YQ; Lin XB; Tan SL; Wang F; Xu P; Fang PF; Liu YP; Xiang DX; Zhang BK
    Ther Drug Monit; 2017 Aug; 39(4):422-428. PubMed ID: 28604474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacokinetic/pharmacodynamic analysis of a standard voriconazole regimen in different CYP2C19 genotypes by Monte Carlo simulation.
    Liao S; Ge T; Zhu L; Zhao Y; Yang J; Xu G
    Pharmazie; 2015 May; 70(5):306-9. PubMed ID: 26062298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetic implementation for CYP2C19 and pharmacokinetics of voriconazole in children with malignancy or inborn errors of immunity.
    Shoji K; Hikino K; Saito J; Matsui T; Utano T; Takebayashi A; Tomizawa D; Kato M; Matsumoto K; Ishikawa T; Kawai T; Nakamura H; Miyairi I; Terao C; Mushiroda T
    J Infect Chemother; 2024 Dec; 30(12):1280-1288. PubMed ID: 38897411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults.
    Friberg LE; Ravva P; Karlsson MO; Liu P
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3032-42. PubMed ID: 22430956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High voriconazole target-site exposure after approved sequence dosing due to nonlinear pharmacokinetics assessed by long-term microdialysis.
    Kirbs C; Kluwe F; Drescher F; Lackner E; Matzneller P; Weiss J; Zeitlinger M; Kloft C
    Eur J Pharm Sci; 2019 Apr; 131():218-229. PubMed ID: 30731238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2C19 Phenotype and Body Weight-Guided Voriconazole Initial Dose in Infants and Children after Hematopoietic Cell Transplantation.
    Takahashi T; Mohamud MA; Smith AR; Jacobson PA; Jaber MM; Alharbi AF; Fisher J; Kirstein MN
    Antimicrob Agents Chemother; 2021 Aug; 65(9):e0062321. PubMed ID: 34097481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of voriconazole and the role of CYP2C19 genotype on treatment optimization in pediatric patients.
    Hu L; Huang S; Huang Q; Huang J; Feng Z; He G
    PLoS One; 2023; 18(9):e0288794. PubMed ID: 37695751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.